共 60 条
[1]
Jiang C(2022)Chronic comorbid conditions among adult cancer survivors in the United States: results from the National Health Interview Survey, 2002–2018 Cancer 128 828-838
[2]
Deng L(2021)Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients Expert Rev Pharmacoecon Outcomes Res 21 511-518
[3]
Karr MA(2021)The impact of COVID-19 on obstetrics and gynaecology trainees; how do we move on? Facts Views Vis Obgyn 13 9-14
[4]
Elsamany S(2019)Early breast cancer: ESMO Clinical Practice Guidelines for dignosis, treatment and follow-up Ann Oncol 30 1194-1220
[5]
Elsisi GH(2021)The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology Expert Rev Pharmacoecon Outcomes Res 21 503-509
[6]
Hassanin F(2016)Administrative risk quantification of subcutaneous and intravenous therapies in Italian centers utilizing the Failure Mode and Effects Analysis approach Clinicoecon Outcomes Res 8 353-359
[7]
Mallick R(2021)Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study Lancet Oncol 22 85-97
[8]
Odejnmi F(2017)Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer N Engl J Med 377 122-131
[9]
Sideris M(2015)Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer N Engl J Med 372 724-734
[10]
Cardoso F(2013)Subcutaneous trastuzumab (Herceptin): a UK Time and motion study in comparison with intravenous formulation for the treatment of patients with HER2-positive early breast cancer Advances in Breast Cancer Res 2 133-140